Scientific Publications

Search by Keyword(s)
Found 13 results

Filters: Author is Wagle, N  [Clear All Filters]

Search Results

  • Showing 1-13 of 13 Results
2014
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.Perry, JA, Kiezun A., Tonzi P., Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E., Pedamallu CS, Helman E., Taylor-Weiner A., McKenna A., Deluca DS, Lawrence MS, Ambrogio L., Sougnez C., Sivachenko A., Walensky LD, Wagle N., et al. Proceedings of the National Academy of Sciences of the United States of America, 2014/12/15, (2014) Read More / View Supplemental Materials
Abstract
Response and acquired resistance to everolimus in anaplastic thyroid cancer.Wagle, N., Grabiner BC, Van Allen EM, Amin-Mansour A., Taylor-Weiner A., Rosenberg M., Gray N., Barletta JA, Guo Y., Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G., Kwiatkowski DJ, Carter SL, Sabatini DM, Jänne PA, Garraway LA, and Lorch JH The New England journal of medicine, 2014/10/09, Volume 371, Issue 15, p.1426-33, (2014) Read More / View Supplemental Materials
Abstract
Assessing the clinical utility of cancer genomic and proteomic data across tumor types.Yuan, Y., Van Allen EM, Omberg L., Wagle N., Amin-Mansour A., Sokolov A., Byers LA, Xu Y., Hess KR, Diao L., Han L., Huang X., Lawrence MS, Weinstein J. N., Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G., and Liang H. Nature biotechnology, 2014/07/01, Volume 32, Issue 7, p.644-52, (2014) Read More / View Supplemental Materials
Abstract
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.Van Allen, EM, Wagle N., Stojanov P., Perrin DL, Cibulskis K., Marlow S., Jane-Valbuena J., Friedrich DC, Kryukov G., Carter SL, McKenna A., Sivachenko A., Rosenberg M., Kiezun A., Voet D., Lawrence M., Lichtenstein LT, Gentry JG, Huang FW, Fostel J., et al. Nature medicine, 2014/06/01, Volume 20, Issue 6, p.682-8, (2014) Read More / View Supplemental Materials
Abstract
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib.Wagle, N., Grabiner BC, Van Allen EM, Hodis E., Jacobus S., Supko JG, Stewart M., Choueiri TK, Gandhi L., Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S., Loda M., Shapiro GI, Sabatini DM, Lander E. S., Gabriel SB, Kantoff PW, et al. Cancer discovery, 2014/03/27, (2014) Read More / View Supplemental Materials
Abstract
2013
Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.Van Allen, EM, Foye A., Wagle N., Kim W., Carter SL, McKenna A., Simko JP, Garraway LA, and Febbo PG Prostate cancer and prostatic diseases, 2013/12/24, (2013) Read More / View Supplemental Materials
Abstract
Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Wright, AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E., Van Hummelen P., Macconaill LE, Shoni M., Wagle N., Jones RT, Quick CM, Laury A., Katz IT, Hahn WC, Matulonis UA, and Hirsch MS Cancer, 2013/11/01, Volume 119, Issue 21, p.3776-83, (2013) Read More / View Supplemental Materials
Abstract
Clinical Analysis and Interpretation of Cancer Genome Data.Van Allen, EM, Wagle N., and Levy MA Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013/04/15, (2013) Read More / View Supplemental Materials
Abstract
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.Whittaker, SR, Theurillat JP, Van Allen E., Wagle N., Hsiao J., Cowley GS, Schadendorf D., Root DE, and Garraway LA Cancer discovery, 2013/01/03, (2013) Read More / View Supplemental Materials
Abstract
2012
A landscape of driver mutations in melanoma.Hodis, E., Watson IR, Kryukov GV, Arold ST, Imielinski M., Theurillat JP, Nickerson E., Auclair D., Li L., Place C., Dicara D., Ramos AH, Lawrence MS, Cibulskis K., Sivachenko A., Voet D., Saksena G., Stransky N., Onofrio RC, Winckler W., et al. Cell, 2012/07/20, Volume 150, Issue 2, p.251-63, (2012) Read More / View Supplemental Materials
Abstract
Melanoma genome sequencing reveals frequent PREX2 mutations.Berger, MF, Hodis E., Heffernan TP, Deribe YL, Lawrence MS, Protopopov A., Ivanova E., Watson IR, Nickerson E., Ghosh P., Zhang H., Zeid R., Ren X., Cibulskis K., Sivachenko AY, Wagle N., Sucker A., Sougnez C., Onofrio R., Ambrogio L., et al. Nature, 2012/05/09, Volume 485, Issue 7399, p.502-6, (2012) Read More / View Supplemental Materials
Abstract
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.Wagle, N., Berger MF, Davis MJ, Blumenstiel B., DeFelice M., Pochanard P., Ducar M., Van Hummelen P., Macconaill LE, Hahn WC, Meyerson M., Gabriel SB, and Garraway LA Cancer discovery, 2012/01/01, Volume 2, Issue 1, p.82-93, (2012) Read More / View Supplemental Materials
Abstract
2011
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Wagle, N., Emery C., Berger MF, Davis MJ, Sawyer A., Pochanard P., Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M., and Garraway LA Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011/08/01, Volume 29, Issue 22, p.3085-96, (2011) Read More / View Supplemental Materials
Abstract
  • Showing 1-13 of 13 Results